Platelet-derived Growth Factor (pdgf) Or Derivative Patents (Class 514/8.2)
-
Publication number: 20110117053Abstract: The invention provides methods and compositions for reducing or preventing fibrosis in a subject suffering from a fibrotic disorder by administering a therapeutically effective amount of at least one antagonist to the cytokine thymic stromal lymphopoietin to the subject. In one embodiment, the methods and compositions further comprise administering at least one additional antagonist to an additional profibrotic cytokine, growth factor or chemokine.Type: ApplicationFiled: January 24, 2011Publication date: May 19, 2011Applicant: AMGEN INC.Inventors: Michael R. COMEAU, David R. FITZPATRICK
-
Publication number: 20110117167Abstract: Compositions and methods for tissue repair are provided including cell binding peptides and growth factor binding peptides. The cell binding peptides bind to one or more of stem cells, fibroblasts, or endothelial cells. The growth factor binding peptides include platelet derived growth factor (PDGF) binding peptides and growth differentiation factor (GDF) binding peptides. The tissue for repair includes tendon, muscle, connective tissue, ligament, cardiac tissue, vascular tissue, or dermis. Implantable devices for tissue repair are provided to which the cell and growth factor binding peptides are attached, such as acellular extracellular matrix having attached binding peptide.Type: ApplicationFiled: November 18, 2010Publication date: May 19, 2011Applicant: AFFINERGY, INC.Inventors: Isaac Gilliam Sanford, Michelle Steffen Jansen, Paul Theodore Hamilton, Jonathan Allen Hodges, Shrikumar Ambujakshan Nair, Yuchen Chen, Martyn Kerry Darby, Hanne Gron, Ganesan Sathya
-
Publication number: 20110117170Abstract: The present invention comprises compositions, methods, and devices for delivering angiogenic factors and signaling molecules to a target tissue, and controlling the release of these factors and signaling molecules to spatially and temporally restrict their release and dissemination, for the purposed promoting angiogenesis in target tissues.Type: ApplicationFiled: June 1, 2009Publication date: May 19, 2011Inventors: Lan Cao, David J. Mooney
-
Publication number: 20110117168Abstract: Compositions and methods for tissue repair are provided including cell binding peptides and growth factor binding peptides. The cell binding peptides bind to one or more of stem cells, fibroblasts, or endothelial cells. The growth factor binding peptides include platelet derived growth factor (PDGF) binding peptides and growth differentiation factor (GDF) binding peptides. The tissue for repair includes tendon, muscle, connective tissue, ligament, cardiac tissue, vascular tissue, or dermis. Implantable devices for tissue repair are provided to which the cell and growth factor binding peptides are attached, such as acellular extracellular matrix having attached binding peptide.Type: ApplicationFiled: November 18, 2010Publication date: May 19, 2011Applicant: AFFINERGY, INC.Inventors: Ganesan Sathya, Michelle Steffen Jansen, Paul Theodore Hamilton, Jonathan Allen Hodges, Shrikumar Ambujakshan Nair, Hanne Gron
-
Publication number: 20110117018Abstract: The present invention relates to compositions, methods and kits for the treatment of bone particularly impaired or damaged bone.Type: ApplicationFiled: June 18, 2010Publication date: May 19, 2011Applicant: BioMimetic Therapeutics, Inc.Inventors: Charles E. HART, Jeffrey O. HOLLINGER, Samuel E. LYNCH
-
Patent number: 7943573Abstract: The present invention relates to compositions and methods for use in osteodistraction procedures. In one embodiment, a method of stimulating osteogenesis during and/or following bone distraction comprises providing a composition comprising a PDGF solution disposed in a biocompatible matrix and applying the composition to at least one site of bone distraction.Type: GrantFiled: February 9, 2009Date of Patent: May 17, 2011Assignee: BioMimetic Therapeutics, Inc.Inventors: Samuel E. Lynch, Charles E. Hart, Michael G. Ehrlich, Douglas C. Moore
-
Publication number: 20110110888Abstract: A system and method for producing a scaffold coated and/or impregnated with at least one bioactive agent. This is accomplished by culturing at least one cell in the same medium as a scaffold, but without physical contact between the at least one cell and the scaffold. The system includes a container having a surface defining an interior compartment. A medium is disposed within the interior compartment. At least one cell is disposed within the medium, the at least one cell being capable of producing at least one bioactive agent. Further, a scaffold is disposed within the medium. The scaffold is physically separated from the at least one cell such that there is no contact between the scaffold and the at least one cell. Thus, as the at least one cell produces at least one bioactive agent, such as a growth factor, the at least one bioactive agent enters the medium, and contacts and coats and/or impregnates the scaffold.Type: ApplicationFiled: June 26, 2009Publication date: May 12, 2011Inventors: Hai-Qing Xian, Jian Q. Yao, Hali Wang, Massoud Daheshia, Hui Liu
-
Publication number: 20110111028Abstract: Compositions and methods for repairing a ruptured connective tissue are disclosed. The composition may include a first biocompatible material to provide a scaffold for connective tissue cell growth and tissue repair. This first biocompatible material may withstand a tensile load of up to 250 N. The composition may also include a second biocompatible material including at least one bioactive agent that can stimulate connective tissue cell growth and tissue repair. The method may include positioning a first end of the first biocompatible material adjacent a first end of a ruptured connective tissue, positioning a second end of the first biocompatible material adjacent a second end of the ruptured connective tissue, and anchoring the first biocompatible material to the first and second tendon ends. The method may alternatively comprise or further include positioning a second biocompatible material between the first and second ends of the ruptured connective tissue.Type: ApplicationFiled: December 22, 2008Publication date: May 12, 2011Inventors: Hali Wang, Jian Q. Yao
-
Publication number: 20110104132Abstract: There is provided a composition for controlling formation and/or stabilization of a blood vessel comprising a first isolated nucleic acid molecule that encodes a FGF-9 polypeptide and optionally one or more isolated nucleic acid molecule that encodes another angiogenic polypeptide. There is provided a composition for controlling formation and/or stabilization of a blood vessel comprising an isolated. The compositions provided herein may be useful for controlling angiogenesis and/or vasculogenesis.Type: ApplicationFiled: May 1, 2009Publication date: May 5, 2011Applicant: University of Western OntarioInventors: J. Geoffrey Pickering, Zengxuan Nong, Matthew Frontini
-
Publication number: 20110105959Abstract: Methods for promoting osteogenesis to accelerate or enhance bone fracture healing, treat bone defects, and enhance bone formation are disclosed. The methods rely on in vivo or ex vivo modulation of an arachidonic acid metabolic or signaling pathway in general, and, in particular, utilize 5-lipoxygenase inhibitors, leukotriene A4 hydrolase inhibitors, and/or leukotriene B4 receptor antagonists. These molecules can be delivered alone or in combination with one or more agents that inhibit bone resorption, regulate calcium resorption from bone, enhance bone accumulation, enhance bone formation, induce bone formation, impair growth of microorganisms, reduce inflammation, and/or reduce pain.Type: ApplicationFiled: August 20, 2010Publication date: May 5, 2011Applicant: ACCELALOX, INC.Inventor: James Patrick O'Connor
-
Publication number: 20110097301Abstract: The present disclosure relates to controlling the release of growth factors for the promotion of angiogenesis. The growth factors or a polymer matrix are modified by photoactive compounds, such that the growth factors are not released into an active form until they are irradiated with light. The disclosure also relates to tissue engineering scaffolds comprising one or more polymers and at least two growth factors.Type: ApplicationFiled: October 26, 2009Publication date: April 28, 2011Inventor: Seth Adrian Miller
-
Patent number: 7923432Abstract: The present invention relates to the design and composition of a depot implant for optimal delivery of growth factors to treat bone avascular necrosis, in that such depot implant is constructed to be in a cylinder (rod) or sphere shape and have a natural or synthetic polymer scaffold with or without impregnated calcium phosphate particles. The density of the depot is higher than a typical BMP sponge carrier to facilitate its implantation and slower release of the growth factor. The scaffold is such that it has adequate porosity and pore size to facilitate growth factor seeding and diffusion throughout the whole of the bone structure resulting in increased new blood vessel growth and density in the avascular necrotic bone. In addition, the shape of the depot implant allows for delivery through a cannula or large bore needle.Type: GrantFiled: November 9, 2006Date of Patent: April 12, 2011Inventor: William F. McKay
-
Publication number: 20110076317Abstract: The present invention is directed to treatment methods for a disease or condition, in a subject in need of such treatment, that provide alternatives to treatment by injection that give, relative to treatment by injection, improved treatment outcomes, 100% treatment compliance, reduced side effects, and rapid establishment and/or termination of substantial steady-state drug delivery. The method typically includes providing continuous delivery of a drug from an implanted osmotic delivery device, wherein substantial steady-state delivery of the drug at therapeutic concentrations is typically achieved within about 7 days or less after implantation of the osmotic delivery device in the subject and the substantial steady-state delivery of the drug from the osmotic delivery device is continuous over a period of at least about 3 months. In one embodiment, the present invention is directed to treatment of type 2 diabetes mellitus using incretin mimetics.Type: ApplicationFiled: September 21, 2010Publication date: March 31, 2011Inventors: Thomas R. Alessi, Kenneth L. Luskey
-
Publication number: 20110070188Abstract: Improved biodegradable and bioabsorbable BAB-block copolymers exhibiting reverse thermal gellation properties, and aqueous polymer compositions including the BAB-block copolymers, are provided. Methods of making the improved BAB-block copolymers and compositions including the same are also provided.Type: ApplicationFiled: September 20, 2010Publication date: March 24, 2011Applicant: Protherics Salt Lake City, Inc.Inventors: Kirk D. FOWERS, Ramesh C. RATHI, Ai-Zhi PIAO
-
Publication number: 20110052588Abstract: Materials and methods for treating hepatocellular carcinoma in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of a zvegf3 antagonist in combination with a pharmaceutically acceptable delivery vehicle. Zvegf3 antagonists include anti-zvegf3 antibodies, mitogenically inactive receptor-binding zvegf3 variant polypeptides, and inhibitory polynucleotides.Type: ApplicationFiled: March 23, 2010Publication date: March 3, 2011Applicant: Zymogenetics, Inc.Inventor: Thomas E. Palmer
-
Publication number: 20110052715Abstract: Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Nanoparticle forms of thyroid hormone or thyroid hormone analogs as well as uses thereof are also disclosed.Type: ApplicationFiled: June 15, 2010Publication date: March 3, 2011Inventors: Paul J. Davis, Faith B. Davis, Shaker A. Mousa, Gennadi V. Glinsky, Aleck Hercbergs
-
Patent number: 7897164Abstract: Compositions for nucleus pulposus regeneration is provided. Such composition may comprise a scaffolding material and a pore creating agent dispersed within the scaffolding material. The pore creating agent is removed from the scaffolding material in vivo, after the composition is administered to a patient. The pore creating agent may include an active agent, such as a growth factor, which may be released as the pore creating agent is being gradually removed from the scaffolding material. In addition, removal of the pore creating agent results in a porous scaffold for cells capable of regeneration of nucleus pulposus, either existing in situ or delivered separately, to attach to for further proliferation and regeneration.Type: GrantFiled: October 30, 2008Date of Patent: March 1, 2011Inventor: Jeffrey L. Scifert
-
Publication number: 20110046606Abstract: Catheter injectable depot compositions are provided that include a bioerodible, biocompatible polymer, a solvent having miscibility in water of less than or equal to 7 wt. % at 25° C., in an amount effective to plasticize the polymer and form a gel therewith, a thixotropic agent, and a beneficial agent. The solvent comprises an aromatic alcohol, an ester of an aromatic acid, an aromatic ketone, or mixtures thereof. The compositions are have substantially improved the shear thinning behavior and reduced injection force, rendering the compositions readily implanted beneath a patient's body surface by injection.Type: ApplicationFiled: October 18, 2010Publication date: February 24, 2011Inventors: Guohua Chen, Paul R. Houston, Lothar Kleiner, John J. Spaltro
-
Publication number: 20110038946Abstract: A biodegradable polyurethane scaffold, comprising at least one polyisocyante, polyisocyanate prepolymer, or both, at least one polyester polyol, at least one catalyst, wherein the density of said scaffold is from about 50 to about 250 kg m-3 and the porosity of the scaffold is greater than about 70 (vol %) and at least 50% of the pores are interconnected with another pore, and wherein the scaffold incorporates at least one biologically active component in powder form.Type: ApplicationFiled: September 5, 2008Publication date: February 17, 2011Inventors: Scott A. Guelcher, Andrea E. Hafeman
-
Publication number: 20110038921Abstract: The present invention provides methods and compositions for sequentially and separately reducing infection and/or inflammation and regenerating tissue at a lesion site, by contacting the lesion site with a biodegradable scaffold that first delivers one or more agents at the lesion site to reduce infection and/or inflammation and then delivers one or more agents to regenerate tissue at the lesion site after inflammation is reduced.Type: ApplicationFiled: August 13, 2010Publication date: February 17, 2011Inventors: Xuejun Wen, Keith L. Kirkwood
-
Publication number: 20110033503Abstract: Described is a spray-on hydrogel comprising water-soluble PEG polymers that cross-link in situ to form a hydrogel such that the cross-links are reversible. The hydrogel can be useful as a drug delivery composition, wound dressing or surgery adjuvant. Polyethylene glycol polymer and cross-linker solutions are sprayed simultaneously through a common orifice. Cross-linking via formation of thioether or disulfide bonds is initiated upon mixing, providing rapid gelation. The hydrogel components can be derivatized with RGD peptides or analogs thereof to promote retention in/on a body compartment such as the skin, surface of the eye, or a mucosa such as the vaginal mucosa. The cross-links are reversed using a reducing solution enabling easy removal of the hydrogel by dissolution. Processes for preparation of the cross-linker, RGD derivatized PEG and RGD-linked agents are also disclosed.Type: ApplicationFiled: April 23, 2008Publication date: February 10, 2011Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Patrick J. Sinko, Stanley Stein, Anupa R. Menjoge, Simi Gunaseelan, Siva Naga Sree priay Anumolu, Raghavandra Navath
-
Publication number: 20110027221Abstract: The present invention provides a recombinant fusion protein which stimulates the rejuvenation and reactivation of skin and epidermal cells for improving skin appearance, smoothing wrinkles and freckles, and whitening skin. Particularly, the present invention provides various types of products for improving skin, which contain recombinant fusion protein of human serum albumin (HSA) with cytokine peptides (EGF, FGF, KGF, HGH, HGF, PDGF, GCSF, interferon, IL-11 or IGF) by genetic engineering technology. The fusion protein can be used independently or in a combination or combination with yeast fermentation products, or with varied emulsifiers, thickeners, moisturizer, preservatives, yeasts and ferments.Type: ApplicationFiled: September 24, 2008Publication date: February 3, 2011Applicants: TIANJIN SINOBIOTECH LTD., FORTUNEROCK, INC. USAInventors: Yan Fu, Zailin Yu
-
Publication number: 20110027363Abstract: Osteogenic compositions are formed from a coprecipitate that contains at least one insoluble calcium salt and at least one osteogenic protein, the coprecipitate being in divided form. A process for preparing the coprecipitate in divided form contains at least one insoluble calcium salt and at least one complex between an osteogenic protein and a polysaccharide. The invention also relates to the formulations, pharmaceutical products, kits and medical devices comprising the coprecipitate.Type: ApplicationFiled: November 19, 2009Publication date: February 3, 2011Applicant: ADOCIAInventors: Remi SOULA, Olivier SOULA, Gerard SOULA
-
Publication number: 20110027257Abstract: The present disclosure relates to a clottable concentrate of platelet growth factors for therapeutic and/or cosmetic use, preferably comprising the growth factors PDGF, TGT-?, IGF, EGF, CTGF, bFGF and VEGF. In a preferred embodiment, the clottable concentrate of platelet growth factors does not induce blood cell-related transfusion reactions. The present disclosure also relates to a method for preparing a clottable concentrate of platelet growth factors including the steps of contacting a platelet concentrate with a solvent and/or a detergent, incubating the platelet concentrate with the solvent and/or detergent for a period of at least 5 minutes to 6 hours, at a pH maintained in a range from about 6.0 to about 9.0, and at a temperature within the range of from 2° C. to 50° C., preferably within the range of from 25° C. to 45° C., and removing the solvent and/or the detergent by oil extraction and/or chromatographic means.Type: ApplicationFiled: January 7, 2009Publication date: February 3, 2011Applicant: GWO REI BIOMEDICAL TECHNOLOGY CORPORATIONInventors: Thierry Burnouf, Cheng-Yao Su
-
Publication number: 20110020271Abstract: The present invention provides compositions comprising isolated elastin and a pharmaceutically acceptable carrier wherein the human elastin is substantially insoluble in water with a molecular weight greater than 100 kDa. The present invention further provides methods and kits for soft tissue augmentation.Type: ApplicationFiled: May 20, 2010Publication date: January 27, 2011Applicant: Humacyte, Inc.Inventors: Laura E. Niklason, Yuling Li, Heather Prichard, Shannon Dahl, Juliana Blum
-
Publication number: 20110008458Abstract: A sub-atmospheric, negative pressure is applied to a growth factor starting material, such as whole blood, to release growth factors and plasma in a non-destructive medium. The released growth factors having a weight of about 70-76 kDaltons are applied in either a filtered or unfiltered state to a wound to promote healing of the wound. The released growth factors are applied topically to the area of a surface wound to effect healing. The released growth factors are also injected into soft tissue, such as a torn tendon, to promote tissue growth and healing. The growth factors are released in one method from a patient's own blood. In another method the growth factors are released from a whole blood source and freeze dried by conventional lyophilization. Then at a later date, the freeze dried product is reconstituted by normal saline for treatment of a patient's wound or for use in a surgical procedure.Type: ApplicationFiled: July 9, 2009Publication date: January 13, 2011Inventors: James Gandy, Robert J. Brandt, Ryan N. Brandt, Clark Galen, Joseph Greco, John Kiwczak
-
Publication number: 20110002880Abstract: The invention relates to a material for wound healing and skin reconstruction containing a peptide, wherein the peptide is a self-assembling peptide which is an amphiphilic peptide having 8 to 200 amino acid residues with periodic repeats of alternating hydrophilic amino acids and hydrophobic amino acids, and forms a stable ?-sheet structure in an aqueous solution in the presence of a monovalent ion. The material for wound healing and skin reconstruction of the present invention is capable of healing a wound area of mammals quicker than spontaneous recovery without leaving any scars, wherein the material has no potential risk of infectious disease such as virus transmission.Type: ApplicationFiled: December 4, 2008Publication date: January 6, 2011Applicant: 3-D MATRIX, LTD.Inventors: Kentaro Takamura, Jiro Takei
-
Publication number: 20100330050Abstract: The present invention relates to methods and compositions for stimulating the proliferation of cardiomyocytes for enhancement of cardiac repair. The invention is based on the discovery that upon contact with stem cells, or conditioned media derived from said stem cells, terminally differentiated cardiomyocytes can be stimulated to enter the cell cycle. Additionally, scaffolds capable of attracting stem cells to the area of implantation have been shown to induce cardiomyocyte proliferation. The present invention further relates to the discovery that the Wnt-5A ligand, which binds to the frizzled receptor (fz), functions to stimulate cardiomyocyte proliferation. The methods and compositions of the invention may be used in the treatment of cardiac disorders including, but not limited to, myocardial dysfunction or infarction.Type: ApplicationFiled: May 17, 2010Publication date: December 30, 2010Inventors: Sergey V. Doronin, Glenn Gaudette, Richard B. Robinson, Michael R. Rosen, Ira S. Cohen, Peter R. Brink
-
Publication number: 20100322872Abstract: The present invention provides a method for prophylaxis and therapy of infectious diseases caused by microorganisms present in biofilms adherent to cell surfaces comprising the step of administering to an individual in need thereof a composition comprising a combination of at least one compound chosen from the group of peroxidase, lactoferrin, lactoferrin peptides, lysozyme and immunoglobulins and at least one growth factor.Type: ApplicationFiled: August 3, 2010Publication date: December 23, 2010Inventor: Jean-Paul Perraudin
-
Publication number: 20100305500Abstract: Embodiments of the invention relate to hyaluronidase as an adjuvant to increase the injection volume and dispersion of large diameter synthetic membrane vesicles containing one or more therapeutic agents. In particular, embodiments of the invention relate to compositions comprising hyaluronidase and large diameter synthetic membrane vesicles containing a therapeutic agent, and methods of administration of the same. Methods of making large diameter synthetic membrane vesicles containing an active pharmaceutical ingredient and their use in combination with hyaluronidase as medicaments are provided.Type: ApplicationFiled: May 28, 2010Publication date: December 2, 2010Applicant: PACIRA PHARMACEUTICALS, INC.Inventors: William LAMBERT, Jason REXROAD
-
Publication number: 20100303886Abstract: Described, in certain aspects of the invention, are multilaminate medical graft products, as well as methods for preparing and using the same. An illustrative multilaminate medical graft product of the invention comprises a first layer of remodelable extracellular matrix (ECM) material bonded to a second layer of remodelable ECM material, wherein the first material layer is enriched with a growth factor relative to the second material layer. Such a remodelable ECM material may be comprised of submucosa from a warm-blooded vertebrate, for example, porcine small intestinal submucosa (SIS).Type: ApplicationFiled: August 12, 2010Publication date: December 2, 2010Inventor: Abram D. Janis
-
Publication number: 20100303793Abstract: An agonist of the non-proteolytically activated thrombin receptor and an angiogenic growth factor can be used in combination in methods of therapy to stimulate cardiac revascularization, to stimulate vascular endothelial cell proliferation, to stimulate vascular endothelial cell migration and to promote repair of cardiac tissue.Type: ApplicationFiled: April 10, 2008Publication date: December 2, 2010Inventors: Barbara Olszewska-Pazdrak, Darrell H. Carney
-
Publication number: 20100297238Abstract: A functionalized electrospun matrix for the controlled-release of biologically active agents, such as growth factors, is presented. The functionalized matrix comprises a matrix polymer, a compatibilizing polymer and a biomolecule or other small functioning molecule. In certain aspects the electrospun polymer fibers comprise at least one biologically active molecule functionalized with low molecular weight heparin.Type: ApplicationFiled: April 27, 2010Publication date: November 25, 2010Inventors: Kristi L. Kiick, Nori Yamaguchi, John Rabolt, Cheryl Casper
-
Publication number: 20100291069Abstract: Maternal diabetes can lead to a developmental malformation of an embryo. A developmental malformation caused by maternal diabetes is commonly referred to as a diabetic embryopathy. There is currently no effective treatment for reducing or inhibiting a diabetic embryopathy. To this end, the present invention is drawn to novel methods of treating a diabetic embryopathy.Type: ApplicationFiled: May 13, 2010Publication date: November 18, 2010Applicant: UNIVERSITY OF MARYLAND, BALTIMOREInventors: E. Albert REECE, Zhiyong ZHAO, Peixin YANG
-
Publication number: 20100274362Abstract: Mixtures, such as gels or pastes, comprising freeze-milled cartilage particles and exogenous growth factors are used for repairing chondral defects. Such mixtures may be applied to constructs comprising cancellous bone for implantation at the defect site. Suitable growth factors include variants of FGF-2, particularly variants that include a sole amino acid substitution for asparagine at amino acid 111 of the ?8-?9 loop of the FGF-2 peptide. Such FGF-2 variants are released slowly and continuously at a constant rate from cartilage pastes. In other embodiments, the amino acid substituted for asparigine is glycine. Other variants that may be used include FGF-9 variants having truncated chains and a sole amino acid substitution in the ?8-?9 loop of the FGF-9 peptide either for tryptophan at amino acid 144 or for asparagine at amino acid 143.Type: ApplicationFiled: January 14, 2010Publication date: October 28, 2010Inventors: Avner Yayon, Katherine G. Truncale, Hilla Barkay-Olami, Alex B. Callahan, Arthur A. Gertzman, Yen-Chen Huang, Morris L. Jacobs, John C. Munson, Eric J. Semler, Roman Shikhanovich, Baruch Stern, Moon Hae Sunwoo, William W. Tomford, Judith I. Yannariello-Brown
-
Publication number: 20100254901Abstract: Disclosed herein are aptamers that comprise a nucleic acid sequence that has a specific affinity for a target. These aptamers can be used as delivery vehicles to deliver specific agents to particular sites. Alternatively, targeted aptamers can also be used with detection techniques to determine the presence of absence of specific targets in heterogeneous backgrounds.Type: ApplicationFiled: July 28, 2006Publication date: October 7, 2010Inventor: Cassandra L. Smith
-
Publication number: 20100247651Abstract: The present invention provides compositions and methods for treating an osteochondral defect. In one embodiment, provided is a composition for treating an osteochondral defect comprising a biphasic biocompatible matrix and platelet derived growth factor (PDGF), wherein the biphasic biocompatible matrix comprises a scaffolding material and wherein the scaffolding material forms a porous structure comprising an osseous phase and a cartilage phase. In another embodiment, also provided is a method for treating an osteochondral defect in an individual comprising administering to the individual an effective amount of a composition comprising a biphasic biocompatible matrix and PDGF to at least one site of the osteochondral defect, wherein the biphasic biocompatible matrix comprises a scaffolding material and wherein the scaffolding material forms a porous structure comprising an osseous phase and a cartilage phase.Type: ApplicationFiled: March 5, 2010Publication date: September 30, 2010Applicant: BioMimetic Therapeutics, Inc.Inventors: Hans K. KESTLER, Joshua Nickols, Leslie A. Wisner-Lynch, Colleen M. Roden, Yanchun Liu
-
Publication number: 20100239654Abstract: The present invention relates to a pharmaceutical composition for sustained release of a pharmaceutically active compound, the composition comprising a vesicular phospholipid gel. More particularly, the invention relates to a pharmaceutical composition comprising at least one proteinaceous substance as the pharmaceutically active compound in encapsulated form, the at least one proteinaceous substance being a biologically active protein, peptide or polypeptide. Furthermore, the present invention relates to a method for the production of said pharmaceutical composition comprising dual asymmetric centrifugation and to the use of said pharmaceutical composition for immunotherapy and/or for stimulating selective tissue regeneration in the treatment of surgical defects in the course of surgical interventions.Type: ApplicationFiled: January 22, 2010Publication date: September 23, 2010Inventor: Gerhard Winter
-
Patent number: 6447775Abstract: The present invention relates to methods and compositions for preventing the endocytosis and cellular internalization of integral membrane amyloid &bgr;-precursor protein (APP) and its subsequent catabolism by blocking or interfering with the association or binding of APP with members of the low density lipoprotein receptor family.Type: GrantFiled: November 16, 1999Date of Patent: September 10, 2002Assignees: The General Hospital Corporation, American National Red CrossInventors: Dudley K. Strickland, Bradley T. Hyman, Maria Z. Kounnas, Robert D. Moir, Rudolph E. Tanzi, G. William Rebeck